ticlopidine has been researched along with Pneumonia in 15 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
Pneumonia: Infection of the lung often accompanied by inflammation.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This study sought to characterize effects of clopidogrel on the incidence and severity of community-acquired pneumonia (CAP)." | 8.89 | Clopidogrel treatment and the incidence and severity of community acquired pneumonia in a cohort study and meta-analysis of antiplatelet therapy in pneumonia and critical illness. ( Abdel-Latif, A; Charnigo, R; Dunn, SP; Feola, DJ; Gross, AK; Li, Z; Martin, CA; Smyth, SS, 2013) |
| "A 65-year-old man, who had been given a diagnosis of angina pectoris, developed pneumonia 6 months after the initiation of clopidogrel to inhibit platelet aggregation." | 7.76 | [A case of drug-induced pneumonia caused by clopidogrel]. ( Hirata, K; Matsushita, H; Suzumura, T; Tamagaki, G; Watanabe, T; Yamada, S, 2010) |
| "Transient pancytopenia as an adverse hematologic reaction due to ticlopidine." | 7.73 | [Transient pancytopenia due to ticlopidine--a case report]. ( Barg, W; Biełous-Wilk, A; Chmielowicz, B; Grabowski, M; Kopec, A; Panaszek, B, 2005) |
| "To report a case of ticlopidine-induced neutropenia occurring 18 days after discontinuation of the drug." | 7.69 | Delayed neutropenia with ticlopidine. ( Farver, DK; Hansen, LA, 1994) |
| " We analysed adverse events (AEs) consistent with either pulmonary infection or sepsis, and subsequent mortality, in 18,421 PLATO patients treated with ticagrelor or clopidogrel." | 6.79 | Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study. ( Åsenblad, N; Becker, RC; Cannon, CP; Held, C; Husted, SE; James, SK; Siegbahn, A; Steg, PG; Storey, RF; Varenhorst, C; Wallentin, L; Ycas, J, 2014) |
| "Ticlopidine is an antiplatelet agent that has been proven efficacious in preventing vascular events in patients with a history of vasculopathy." | 5.30 | Ticlopidine-associated pancytopenia: implications of an acetylsalicylic acid alternative. ( Armstrong, PW; Brown, NE; Gill, S; Majumdar, S, 1997) |
| " This study sought to characterize effects of clopidogrel on the incidence and severity of community-acquired pneumonia (CAP)." | 4.89 | Clopidogrel treatment and the incidence and severity of community acquired pneumonia in a cohort study and meta-analysis of antiplatelet therapy in pneumonia and critical illness. ( Abdel-Latif, A; Charnigo, R; Dunn, SP; Feola, DJ; Gross, AK; Li, Z; Martin, CA; Smyth, SS, 2013) |
| "Using a mouse model of intra-abdominal sepsis and acute lung injury, we investigated the role of the P2Y12 receptor in neutrophil migration and lung inflammation in P2Y12 null mice and in mice pretreated with the P2Y12 antagonist clopidogrel." | 3.83 | P2Y12 Receptor Modulates Sepsis-Induced Inflammation. ( Kilpatrick, LE; Kunapuli, SP; Liverani, E; Rico, MC; Tsygankov, AY, 2016) |
| "A 65-year-old man, who had been given a diagnosis of angina pectoris, developed pneumonia 6 months after the initiation of clopidogrel to inhibit platelet aggregation." | 3.76 | [A case of drug-induced pneumonia caused by clopidogrel]. ( Hirata, K; Matsushita, H; Suzumura, T; Tamagaki, G; Watanabe, T; Yamada, S, 2010) |
| "Transient pancytopenia as an adverse hematologic reaction due to ticlopidine." | 3.73 | [Transient pancytopenia due to ticlopidine--a case report]. ( Barg, W; Biełous-Wilk, A; Chmielowicz, B; Grabowski, M; Kopec, A; Panaszek, B, 2005) |
| "To report a case of ticlopidine-induced neutropenia occurring 18 days after discontinuation of the drug." | 3.69 | Delayed neutropenia with ticlopidine. ( Farver, DK; Hansen, LA, 1994) |
| " We analysed adverse events (AEs) consistent with either pulmonary infection or sepsis, and subsequent mortality, in 18,421 PLATO patients treated with ticagrelor or clopidogrel." | 2.79 | Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study. ( Åsenblad, N; Becker, RC; Cannon, CP; Held, C; Husted, SE; James, SK; Siegbahn, A; Steg, PG; Storey, RF; Varenhorst, C; Wallentin, L; Ycas, J, 2014) |
| " Proton pump inhibitors cause few adverse effects with short-term use; however, long-term use has been scrutinized for appropriateness, drug-drug interactions, and the potential for adverse effects (e." | 2.48 | Reducing adverse effects of proton pump inhibitors. ( Ament, PW; Dicola, DB; James, ME, 2012) |
| "Gastroesophageal reflux disease (GERD) affects 10% to 20% of the western world's population." | 1.42 | What are the precautions with proton pump inhibitor use for reflux disease? ( Mospan, CM, 2015) |
| "Ticlopidine is an antiplatelet agent that has been proven efficacious in preventing vascular events in patients with a history of vasculopathy." | 1.30 | Ticlopidine-associated pancytopenia: implications of an acetylsalicylic acid alternative. ( Armstrong, PW; Brown, NE; Gill, S; Majumdar, S, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (20.00) | 18.2507 |
| 2000's | 2 (13.33) | 29.6817 |
| 2010's | 10 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Storey, RF | 1 |
| James, SK | 1 |
| Siegbahn, A | 1 |
| Varenhorst, C | 1 |
| Held, C | 1 |
| Ycas, J | 1 |
| Husted, SE | 1 |
| Cannon, CP | 1 |
| Becker, RC | 1 |
| Steg, PG | 1 |
| Åsenblad, N | 1 |
| Wallentin, L | 1 |
| Mospan, CM | 1 |
| Otoshi, T | 1 |
| Kataoka, Y | 1 |
| Nakagawa, A | 1 |
| Otsuka, K | 1 |
| Tomii, K | 1 |
| Liverani, E | 1 |
| Rico, MC | 1 |
| Tsygankov, AY | 1 |
| Kilpatrick, LE | 1 |
| Kunapuli, SP | 1 |
| Eusebi, LH | 1 |
| Rabitti, S | 1 |
| Artesiani, ML | 1 |
| Gelli, D | 1 |
| Montagnani, M | 1 |
| Zagari, RM | 1 |
| Bazzoli, F | 1 |
| Winning, J | 1 |
| Reichel, J | 1 |
| Eisenhut, Y | 1 |
| Hamacher, J | 1 |
| Kohl, M | 1 |
| Deigner, HP | 1 |
| Claus, RA | 1 |
| Bauer, M | 1 |
| Lösche, W | 1 |
| Tamagaki, G | 1 |
| Matsushita, H | 1 |
| Suzumura, T | 1 |
| Watanabe, T | 1 |
| Yamada, S | 1 |
| Hirata, K | 1 |
| Madanick, RD | 1 |
| Ament, PW | 1 |
| Dicola, DB | 1 |
| James, ME | 1 |
| Gross, AK | 1 |
| Dunn, SP | 1 |
| Feola, DJ | 1 |
| Martin, CA | 1 |
| Charnigo, R | 1 |
| Li, Z | 1 |
| Abdel-Latif, A | 1 |
| Smyth, SS | 1 |
| Grabowski, M | 1 |
| Barg, W | 1 |
| Biełous-Wilk, A | 1 |
| Kopec, A | 1 |
| Chmielowicz, B | 1 |
| Panaszek, B | 1 |
| Farver, DK | 1 |
| Hansen, LA | 1 |
| Gill, S | 1 |
| Majumdar, S | 1 |
| Brown, NE | 1 |
| Armstrong, PW | 1 |
| Watanabe, M | 1 |
| Machida, K | 1 |
| Higashimoto, I | 1 |
| Niina, K | 1 |
| Kawabata, M | 1 |
| Osame, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Institute of Emergency and Critical Care Medicine , School of Yang-Ming University[NCT01588886] | 9,000 participants (Actual) | Observational | 2012-03-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for ticlopidine and Pneumonia
| Article | Year |
|---|---|
Proton pump inhibitors: Risks of long-term use.
Topics: Calcium; Cardiovascular Diseases; Clopidogrel; Dementia; Drug Interactions; Fractures, Bone; Gastroi | 2017 |
Proton pump inhibitor side effects and drug interactions: much ado about nothing?
Topics: Anemia, Iron-Deficiency; Anti-Ulcer Agents; Clopidogrel; Drug Interactions; Fractures, Spontaneous; | 2011 |
Reducing adverse effects of proton pump inhibitors.
Topics: Anemia, Iron-Deficiency; Clopidogrel; Clostridioides difficile; Critical Care; Diarrhea; Drug Intera | 2012 |
Clopidogrel treatment and the incidence and severity of community acquired pneumonia in a cohort study and meta-analysis of antiplatelet therapy in pneumonia and critical illness.
Topics: Adult; Aged; Aged, 80 and over; Clopidogrel; Cohort Studies; Community-Acquired Infections; Critical | 2013 |
[Multiple pulmonary nodules due to ticlopidine-induced pneumonitis].
Topics: Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Pneumonia; Radiography, Thoracic; Solita | 1999 |
1 trial available for ticlopidine and Pneumonia
| Article | Year |
|---|---|
Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study.
Topics: Adenosine; Aged; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Platelet A | 2014 |
9 other studies available for ticlopidine and Pneumonia
| Article | Year |
|---|---|
What are the precautions with proton pump inhibitor use for reflux disease?
Topics: Anemia, Iron-Deficiency; Clopidogrel; Community-Acquired Infections; Deficiency Diseases; Drug Inter | 2015 |
Clinical Features and Outcomes of Diffuse Alveolar Hemorrhage During Antithrombotic Therapy: A Retrospective Cohort Study.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cilostazol; Clopidogrel; Connective Tissue Diseases; Female | 2016 |
P2Y12 Receptor Modulates Sepsis-Induced Inflammation.
Topics: Acute Lung Injury; Animals; Blood Platelets; Clopidogrel; Cytokines; Genetic Predisposition to Disea | 2016 |
Anti-platelet drugs and outcome in severe infection: clinical impact and underlying mechanisms.
Topics: Adult; Aged; Animals; Cell Line; Clopidogrel; Female; Fibrin; Gene Expression Profiling; Hemodynamic | 2009 |
[A case of drug-induced pneumonia caused by clopidogrel].
Topics: Aged; Angina Pectoris; Clopidogrel; Humans; Male; Platelet Aggregation Inhibitors; Pneumonia; Ticlop | 2010 |
Side effects of proton pump inhibitors.
Topics: Clopidogrel; Diarrhea; Drug Interactions; Gastroesophageal Reflux; Hip Fractures; Humans; Platelet A | 2012 |
[Transient pancytopenia due to ticlopidine--a case report].
Topics: Aged; Anti-Bacterial Agents; Female; Fibrinolytic Agents; Heart Failure; Humans; Pancytopenia; Pneum | 2005 |
Delayed neutropenia with ticlopidine.
Topics: Aged; Blood Cell Count; Female; Humans; Ischemic Attack, Transient; Neutropenia; Pneumonia; Ticlopid | 1994 |
Ticlopidine-associated pancytopenia: implications of an acetylsalicylic acid alternative.
Topics: Aspirin; Cardiovascular Diseases; Drug Resistance; Fatal Outcome; Female; Humans; Middle Aged; Neutr | 1997 |